Literature DB >> 17911618

A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.

Tjadine M Holling1, Marloes W T Bergevoet, Louis Wilson, Marja C J A Van Eggermond, Erik Schooten, Renske D M Steenbergen, Peter J F Snijders, Martine J Jager, Peter J Van den Elsen.   

Abstract

We investigated the contribution of epigenetic mechanisms in MHC2TA transcriptional silencing in uveal melanoma. Although no correlation was observed between impaired CIITA transcript levels after IFN-gamma induction and DNA methylation of MHC2TA promoter IV (CIITA-PIV), an association was found with high levels of trimethylated histone H3-lysine 27 (3Me-K27-H3) in CIITA-PIV chromatin. The 3Me-K27-H3 modification correlated with a strong reduction in RNA polymerase II-recruitment to CIITA-PIV. Interestingly, we observed that none of these epigenetic modifications affected recruitment of activating transcription factors to this promoter. Subsequently, we demonstrated the presence of the histone methyltransferase EZH2 in CIITA-PIV chromatin, which is known to be a component of the Polycomb repressive complex 2 and able to triple methylate histone H3-lysine 27. RNA interference-mediated down-regulation of EZH2 expression resulted in an increase in CIITA transcript levels after IFN-gamma induction. Our data therefore reveal that EZH2 contributes to silencing of IFN-gamma-inducible transcription of MHC2TA in uveal melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911618     DOI: 10.4049/jimmunol.179.8.5317

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Dynamic patterns of histone lysine methylation in the developing retina.

Authors:  Rajesh C Rao; Kissaou T Tchedre; Muhammad Taimur A Malik; Natasha Coleman; Yuan Fang; Victor E Marquez; Dong Feng Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-29       Impact factor: 4.799

Review 2.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

3.  CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.

Authors:  Priya Londhe; Bo Zhu; Jinu Abraham; Charles Keller; Judith Davie
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

Review 4.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

5.  PU.1 binds to a distal regulatory element that is necessary for B cell-specific expression of CIITA.

Authors:  Hyesuk Yoon; Jeremy M Boss
Journal:  J Immunol       Date:  2010-04-02       Impact factor: 5.422

Review 6.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

7.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.

Authors:  Sara Michel; Michael Linnebacher; Joshua Alcaniz; Maike Voss; Rudolf Wagner; Wolfgang Dippold; Christina Becker; Magnus von Knebel Doeberitz; Soldano Ferrone; Matthias Kloor
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 8.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

9.  IFN-γ Induces Histone 3 Lysine 27 Trimethylation in a Small Subset of Promoters to Stably Silence Gene Expression in Human Macrophages.

Authors:  Yu Qiao; Kyuho Kang; Eugenia Giannopoulou; Celeste Fang; Lionel B Ivashkiv
Journal:  Cell Rep       Date:  2016-09-20       Impact factor: 9.423

Review 10.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.